Member Info for Henley2

What a way to crash the share price!

Put out an RNS on funding without also having lined up the capital raise.

What advice is the CEO getting from the NOMAD?

Not much I would say.

CEO appointed 11 months ago when the share price was 27p.

He has known all along of the need to raise fresh capital and only now issues shares at 1p a 73%discount to the current price. In CVJ we trust. Yeah right. Next capital raise at 0.1p in 18 months time?

Well done BigBiteNow. Great notes and synopsis of yesterday’s presentation.

I sold out early yesterday, then listened to the presentation and immediately bought back on the basis of the reduced P3 trial costs and re-engagement with pharma companies and the statements regarding efficacy against MRSA and minimal risk of liver/kidney toxicity.

I know it’s not the right way to look at things, but we have a JORC copper resource of c.$2.4bn vs a MCAP of $10m!

He already owns the 99 million shares.

He’s buying a few now in the market and no doubt the lemmings will follow and he can punt them out at a higher price.

Why sell now ahead of TO13 flow test?

Why would he take it now?

Better to wait for the results of the flow test results.

If they are good, price goes up and he retains his shares.

If bad, he cashes out at 0.75p.

You don’t understand what a put option is?

He can cash out £750k at anytime up to September 1st regardless of where the share price goes.

He’s quids in!

Why hold the presentation without the JORC RNS?

Be interesting to see where these trade today, given that RG and M&G are putting in £30m at 15p!

Well they have approximately one years cash flow in the bank, so the CEO had better start signing some commercial agreements pretty soon to fund the technology roadmap.

The share price has already fallen 40% from the last placing, so I doubt there will be much appetite from the market to provide further funding, let alone us poor sods who are 90% down from the IPO!

Company is more or less saying that unless they out license the two cancer tests named, there will be a placing in q224.

That should read 4.9bn

$4.9BC65F of the debt transferred over with an average coupon of 1.8%!

What’s not to like about that?

What price is the placing being done at?

If Amati want out, why has the CEO not contacted Bracco or Nukem to purchase their holding.

Nukem increased their stake in August by 0.5% when the share price was 15p, whilst Branco invested in the last capital raise at I think 60p. For little more than £1m they could acquire a 10% stake in the company. It makes no sense to allow a continual drip feed of sales to trash the share price, unless of course they have lost complete faith in the prospects for the company.

seems strange that for a supposed revolution in lung imaging technology, the company seems completely incapable of commercialising the product.

what we don’t need is the ceo/cfo trotting through a 25 page interim results presentation leaving minimal time for questions. we all know what the company does. we require an honest assessment from the new ceo of the company’s commercial development, and more importantly how they intend to finance the company going forward. the time for bull****ting is over.

Did anyone listen to the AGM via the Zoom link?

Did the new CEO address the funding issue or the snails pace in sales post FDA approval?